These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7998128)

  • 1. Clinical experience with a monoclonal interleukin-2 receptor antibody (BT 563) for rejection therapy after orthotopic heart transplantation.
    Iberer F; Tscheliessnigg KH; Freigassner M; Auer T; Kleinert R; Wasler A; Petutschnigg B; Müller H
    Transplant Proc; 1994 Dec; 26(6):3237-9. PubMed ID: 7998128
    [No Abstract]   [Full Text] [Related]  

  • 2. Intragraft monitoring of rejection after prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipients.
    van Gelder T; Mulder AH; Balk AH; Mochtar B; Hesse CJ; Baan CC; Vaessen LM; Weimar W
    J Heart Lung Transplant; 1995; 14(2):346-50. PubMed ID: 7779855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of anti-IL-2-receptor monoclonal antibody BT 563 in treatment of acute interstitial renal rejection.
    Carl S; Wiesel M; Daniel V; Staehler G
    Transplant Proc; 1995 Feb; 27(1):854-5. PubMed ID: 7879205
    [No Abstract]   [Full Text] [Related]  

  • 4. Peripheral blood monitoring during and after rejection-prophylaxis with a monoclonal anti-interleukin-2-receptor antibody in kidney and heart transplant recipients.
    van Gelder T; Knoop CJ; Hesse CJ; Vaessen LM; Balk AH; Yzermans JN; Weimar W
    Transplant Proc; 1995 Feb; 27(1):856-8. PubMed ID: 7879206
    [No Abstract]   [Full Text] [Related]  

  • 5. Influence of the anti-CD25 monoclonal antibody BT563 on clinical and biological rejection after orthotopic liver transplantation.
    Otto G; Hofmann WJ; Gaweco AS; Seelos R; Herfarth C; Meuer S
    Transplant Proc; 1996 Dec; 28(6):3210-1. PubMed ID: 8962244
    [No Abstract]   [Full Text] [Related]  

  • 6. Contribution of the inflammatory response to cardiac allograft rejection: histopathologic analysis of serial endomyocardial biopsies.
    Baan CC; Knoop CJ; van Gelder T; van der Ham F; Zondervan PE; Holweg CT; Mochtar B; Balk AH; Weimar W
    Transplant Proc; 1998 Jun; 30(4):1104-6. PubMed ID: 9636448
    [No Abstract]   [Full Text] [Related]  

  • 7. Quadruple induction immunosuppression after liver transplantation with IL-2 receptor antibody (BT 563) is equally effective and better tolerated than ATG induction therapy.
    Neuhaus B; Keck H; Bechstein WO; Blumhardt G; Langrehr JM; Wiens M; Lemmens HP; Lohmann R; Schlag H; Thalmann U
    Transplant Proc; 1993 Feb; 25(1 Pt 1):587-9. PubMed ID: 8438426
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunosuppression in small bowel transplantation--treatment with a monoclonal IL-2 receptor antibody (NDS 61).
    Schweizer E; Papachrysanthou A; Faendrich F; Deltz E; Schroeder P
    Transplant Proc; 1994 Dec; 26(6):3142-3. PubMed ID: 7998095
    [No Abstract]   [Full Text] [Related]  

  • 9. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
    Langrehr JM; Glanemann M; Guckelberger O; Klupp J; Neumann U; Machens C; Lohmann R; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ
    Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common and sequential overexpression patterns of T-helper cytokines during acute (cellular) rejection, and correlation of proinflammatory cytokine expression with chronic (ductopenic) rejection of human liver allografts: a study under cyclosporine, FK 506, and quadruple BT 563 immunosuppression.
    Gaweco AS; Otto G; Otto HF; Meuer S; Geisse T; Hofmann WJ
    Transplant Proc; 1995 Feb; 27(1):1152-4. PubMed ID: 7533370
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-interleukin-2 receptor (IL-2R) antibody against rejection of organ grafts.
    Kupiec-Weglinski JW; Padberg W; Uhteg LC; Towpik E; Lord RH; Ma L; Diamantstein T; Strom TB; Tilney NL
    Transplant Proc; 1987 Feb; 19(1 Pt 1):591-3. PubMed ID: 2978926
    [No Abstract]   [Full Text] [Related]  

  • 12. CD4 and CD25 monoclonal antibody cocktail in kidney transplant rejection prophylaxis: clinical results of a pilot study.
    Mousson C; Tanter Y; Racadot E; Wijdenes J; Chalopin JM; Chevet D; Hervé P; Rifle G
    Transplant Proc; 1995 Apr; 27(2):1727-8. PubMed ID: 7725472
    [No Abstract]   [Full Text] [Related]  

  • 13. Interleukin-2 receptor antibody vs ATG for induction immunosuppression after liver transplantation: initial results of a prospective randomized trial.
    Lemmens HP; Langrehr JM; Bechstein WO; Blumhardt G; Keck H; Lüsebrink R; Knoop M; Lohmann R; Tullius S; Lobeck H
    Transplant Proc; 1995 Feb; 27(1):1140-1. PubMed ID: 7878826
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody.
    Friend PJ; Rebello P; Oliveira D; Manna V; Cobbold SP; Hale G; Jamieson NV; Jamieson I; Calne RY; Harris DT
    Transplant Proc; 1995 Feb; 27(1):869-70. PubMed ID: 7879212
    [No Abstract]   [Full Text] [Related]  

  • 15. Quadruple induction immunosuppression after liver transplantation with interleukin-2 receptor antibody (BT 563) is equally effective and better tolerated than antithymocyte globulin induction therapy.
    Neuhaus P; Bechstein WO; Blumhardt G; Steffen R; Keck H; Lemmens P; Langrehr JM; Schlag H
    Transplant Proc; 1993 Apr; 25(2):1940-1. PubMed ID: 8470234
    [No Abstract]   [Full Text] [Related]  

  • 16. Interleukin-2 receptor antibody versus antithymocyte globulin as part of quadruple induction therapy after orthotopic liver transplantation: a randomized study.
    Langrehr JM; Guckelberger O; Nüssler N; Radtke A; Lemmens HP; Jonas S; Lohmann R; Tullius S; Steinmüller T; Raakow R; Neumann U; Knoop M; Bechstein WO; Neuhaus P
    Transplant Proc; 1996 Dec; 28(6):3204. PubMed ID: 8962241
    [No Abstract]   [Full Text] [Related]  

  • 17. Blockade of the interleukin (IL)-2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humans.
    van Gelder T; Baan CC; Balk AH; Knoop CJ; Holweg CT; van der Meer P; Mochtar B; Zondervan PE; Niesters HG; Weimar W
    Transplantation; 1998 Feb; 65(3):405-10. PubMed ID: 9484761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac allograft cellular rejection during OKT3 prophylaxis in the absence of sensitization.
    Moore CK; O'Connell JB; Renlund DG; Bristow MR; Hammond EH
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1055-8. PubMed ID: 1899151
    [No Abstract]   [Full Text] [Related]  

  • 19. Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy.
    Lietz K; John R; Beniaminovitz A; Burke EM; Suciu-Foca N; Mancini DM; Edwards NM; Itescu S
    Transplantation; 2003 Mar; 75(6):781-7. PubMed ID: 12660501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD25 monoclonal antibody prevents early rejection in liver transplantation--a pilot study.
    Otto G; Thies J; Kabelitz D; Schlag H; Hofmann WJ; Herfarth C; Meuer S
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1387-9. PubMed ID: 1989246
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.